<p>Astellas Pharma（东京证券交易所代码：4503）已公布其 2026 财年的业绩目标，预计下半年收入为 1.1 万亿日元，基本每股收益为 80.33 日元，剔除非常规项目后的净收入为 1439 亿日元。该公司的收入从 2025 财年下半年的 9767 亿日元和基本每股收益 12.72 日元，增长到 2026 财年上半年的 1.0 万亿日元和 82.44 日元，最终在最新期间达到 1.1 万亿日元和 80.33 日元。在同一时间段内，过去 12 个月的每股收益从 28.35 日元增加到 162.77 日元。对于投资者而言，重点在于过去一年中净利润率的提高所支持的盈利状况，这引发了对这种盈利组合可持续性的深入思考。</p>
<p>查看我们对 Astellas Pharma 的完整分析。</p>
<p>在最新数据公布后，下一步是将这些利润率和盈利趋势与 Astellas Pharma 最常见的市场叙事进行比较，并评估哪些故事仍然得到良好支持，哪些可能变得过时。</p>
<p>查看社区对 Astellas Pharma 的看法</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/752d0c7c-b3bc-4f67-b043-9a093549bae9/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1640" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/752d0c7c-b3bc-4f67-b043-9a093549bae9/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI4"/></p>
<p>东京证券交易所：4503 收入与支出明细截至 2026 年 4 月</p>
<h2>利润率扩展至 13.6%</h2>
<ul>
<li>在过去 12 个月中，Astellas 将 2.1 万亿日元的收入转化为剔除非常规项目后的 2915 亿日元净收入，这意味着净利润率为 13.6%，而一年前为 2.7%。</li>
<li>看涨的投资者指出，这一较高的 13.6% 利润率与过去一年中报告的巨大盈利增长相伴随。同时，看涨叙事假设利润率将在 2029 年前从 15.7% 回落至 12.5%。因此，当前的盈利水平为他们提供了盈利能力的证据，同时也引发了对这种利润率组合在多大程度上能够持续的质疑。</li>
</ul>
<p>在过去 12 个月中，报告的盈利增长了大约 6 倍。</p>
<ul>
<li>过去 12 个月的基本每股收益从上一年末的 28.35 日元上升至最新的 162.77 日元，这一变化与所提到的 474.5% 的盈利增长率相一致。</li>
<li>对于看涨叙事而言，这种每股收益和净收入的跃升支持了更快的成本降低和研发效率已经转化为利润的观点。尽管如此，乐观阵营预计到 2029 年盈利将达到 2539 亿日元，每股收益为 141.8 日元，这低于今天提到的 3229 亿日元的参考点。因此，任何持看涨态度的人都需要将这一强劲的近期每股收益与分析师（包括看涨分析师）仍将中期视为盈利收缩而非简单线性增长的事实进行调和。</li>
</ul>
<p><strong>🐂 Astellas Pharma 看涨案例</strong></p>
<h2>便宜的市盈率和 DCF 差距</h2>
<ul>
<li>该股交易价格为 2291.50 日元，市盈率为 14.1 倍，而同行业平均市盈率为 29.9 倍，JP 制药行业平均市盈率为 15.5 倍。该价格也远低于 DCF 公允价值 4580.24 日元。</li>
<li>批评者指出，即使有这种折扣，分析师预计未来三年盈利将下降约 11.2%，收入将下降约 6.2%。这意味着低市盈率和与 DCF 公允价值的差距可以被解读为机会（如果你认为模型化的盈利下滑过于严厉），或者作为市场已经考虑到这些较弱的前瞻性数字的信号。</li>
</ul>
<h2>看跌案例关注收入萎缩</h2>
<ul>
<li>在过去三个半年度中，收入从 2025 财年下半年的 976,702 百万日元增长到 2026 财年上半年的 1,030,114 百万日元，再到下半年的 1,109,131 百万日元。然而，谨慎观点中提到的分析师模型仍然预测未来几年看跌情况下年收入将下降约 5.4%，共识情况下下降 3.5%。</li>
<li>看跌者认为，关键产品的专利到期和药品定价压力将使得替代收入变得困难。这在他们的情景中反映出来，预计到 2028 年收入将降至 1,648.6 亿日元，盈利降至 1180 亿日元，因此当前的 2915 亿日元净收入和 13.6% 利润率在谨慎投资者评估企业可能面临的独占权丧失和政策变化时，直接与这些预计的较低收入和盈利数字进行权衡。</li>
</ul>
<p><strong>🐻 Astellas Pharma 看跌案例</strong></p>
<h2>下一步</h2>
<p>要了解这些结果如何与长期增长、风险和估值相结合，请查看 Simply Wall St 上关于 Astellas Pharma 的完整社区叙事。将该公司添加到您的观察列表或投资组合中，以便在故事发展时收到提醒。</p>
<p>在 Astellas Pharma 周围的乐观与担忧的混合中，迅速行动并查看细节以了解哪些内容突出是有帮助的。为了权衡故事的两面，回顾 4 个关键奖励和 1 个重要警示信号。</p>
<h2>查看其他信息</h2>
<p>分析师正在预测 Astellas Pharma 的年收入和盈利下降，这引发了对当前盈利和利润率组合在长期持有者中究竟有多持久的质疑。</p>
<p>如果收入潜力缩减让您感到担忧，那么将这种情况与经过筛选的表现稳健且下行风险较低的公司进行比较是有意义的，使用 46 只具有低风险评分的稳健股票。</p>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>并且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

4503

<p>Astellas Pharma（东京证券交易所代码：4503）公布了 2026 财年的业绩报告，第二季度的收入为 1.1 万亿日元，基本每股收益为 80.33 日元，净利润率显著提高至 13.6%，相比去年同期的 2.7% 有了大幅增长。尽管乐观的叙述提到强劲的盈利增长，分析师预测中期可能出现盈利收缩。该股票的市盈率为 14.1 倍，低于行业平均水平，但由于专利到期和价格压力，收入下降的担忧依然存在。投资者被建议在考虑公司未来表现时，兼顾乐观和谨慎的观点</p>

<p>Astellas Pharma (TSE:4503) has laid out its FY 2026 scorecard with second half revenue of ¥1.1t and basic EPS of ¥80.33, alongside net income excluding extraordinary items of ¥143.9b. The company has seen revenue move from ¥976.7b and basic EPS of ¥12.72 in the second half of FY 2025, to ¥1.0t and ¥82.44 in the first half of FY 2026, before reaching ¥1.1t and ¥80.33 in the latest period. Over the same timeframe, trailing twelve month EPS has increased from ¥28.35 to ¥162.77. For investors, the headline here is an earnings profile backed by higher net profit margins over the last year, which invites a closer look at how sustainable this profitability mix may be.</p>
<div class="lb-trans"><p>Astellas Pharma（东京证券交易所代码：4503）已公布其 2026 财年的业绩目标，预计下半年收入为 1.1 万亿日元，基本每股收益为 80.33 日元，剔除非常规项目后的净收入为 1439 亿日元。该公司的收入从 2025 财年下半年的 9767 亿日元和基本每股收益 12.72 日元，增长到 2026 财年上半年的 1.0 万亿日元和 82.44 日元，最终在最新期间达到 1.1 万亿日元和 80.33 日元。在同一时间段内，过去 12 个月的每股收益从 28.35 日元增加到 162.77 日元。对于投资者而言，重点在于过去一年中净利润率的提高所支持的盈利状况，这引发了对这种盈利组合可持续性的深入思考。</p>
</div><p>See our full analysis for Astellas Pharma.</p>
<div class="lb-trans"><p>查看我们对 Astellas Pharma 的完整分析。</p>
</div><p>With the latest figures on the table, the next step is to compare these margins and earnings trends with the most common market narratives around Astellas Pharma and assess which stories still appear well supported and which may be becoming outdated.</p>
<div class="lb-trans"><p>在最新数据公布后，下一步是将这些利润率和盈利趋势与 Astellas Pharma 最常见的市场叙事进行比较，并评估哪些故事仍然得到良好支持，哪些可能变得过时。</p>
</div><p>See what the community is saying about Astellas Pharma</p>
<div class="lb-trans"><p>查看社区对 Astellas Pharma 的看法</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/752d0c7c-b3bc-4f67-b043-9a093549bae9/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA0LTI4" alt="" original-src="https://images.simplywall.st/company/752d0c7c-b3bc-4f67-b043-9a093549bae9/chart/revenue-and-expenses-breakdown?date=2026-04-28"/></p>
<p>TSE:4503 Revenue &amp; Expenses Breakdown as at Apr 2026</p>
<div class="lb-trans"><p>东京证券交易所：4503 收入与支出明细截至 2026 年 4 月</p>
</div><h2>Margins Stretch Out To 13.6%</h2>
<div class="lb-trans"><h2>利润率扩展至 13.6%</h2>
</div><ul>
<li>On a trailing twelve month basis, Astellas converted ¥2.1t of revenue into ¥291.5b of net income excluding extraordinary items, which works out to a 13.6% net margin compared with 2.7% a year earlier.</li>
<li>Bullish investors point to the fact that this higher 13.6% margin sits alongside very large reported earnings growth over the past year. At the same time, the bullish narrative assumes margins ease back from 15.7% to 12.5% by around 2029. The current profitability level therefore gives them evidence of earnings power while also raising the question of how much of this margin profile can realistically be carried forward.</li>
</ul>
<div class="lb-trans"><ul>
<li>在过去 12 个月中，Astellas 将 2.1 万亿日元的收入转化为剔除非常规项目后的 2915 亿日元净收入，这意味着净利润率为 13.6%，而一年前为 2.7%。</li>
<li>看涨的投资者指出，这一较高的 13.6% 利润率与过去一年中报告的巨大盈利增长相伴随。同时，看涨叙事假设利润率将在 2029 年前从 15.7% 回落至 12.5%。因此，当前的盈利水平为他们提供了盈利能力的证据，同时也引发了对这种利润率组合在多大程度上能够持续的质疑。</li>
</ul>
</div><p>Over the last 12 months, reported earnings grew roughly 6x.</p>
<div class="lb-trans"><p>在过去 12 个月中，报告的盈利增长了大约 6 倍。</p>
</div><ul>
<li>Trailing twelve month basic EPS moved from ¥28.35 at the end of the prior year period to ¥162.77 at the latest reading, a change that aligns with the cited 474.5% earnings growth rate.</li>
<li>For the bullish narrative, this kind of jump in EPS and net income supports the view that faster cost reductions and R&amp;D efficiencies are already feeding through to profit. Even so, the optimistic camp is modeling earnings of ¥253.9b and EPS of ¥141.8 by 2029, which is lower than the ¥322.9b reference point cited for today. Anyone leaning bullish therefore needs to reconcile this strong recent EPS with the fact that analysts, including bullish ones, still frame the medium term as earnings contraction rather than simple straight line growth.</li>
</ul>
<div class="lb-trans"><ul>
<li>过去 12 个月的基本每股收益从上一年末的 28.35 日元上升至最新的 162.77 日元，这一变化与所提到的 474.5% 的盈利增长率相一致。</li>
<li>对于看涨叙事而言，这种每股收益和净收入的跃升支持了更快的成本降低和研发效率已经转化为利润的观点。尽管如此，乐观阵营预计到 2029 年盈利将达到 2539 亿日元，每股收益为 141.8 日元，这低于今天提到的 3229 亿日元的参考点。因此，任何持看涨态度的人都需要将这一强劲的近期每股收益与分析师（包括看涨分析师）仍将中期视为盈利收缩而非简单线性增长的事实进行调和。</li>
</ul>
</div><p><strong>🐂 Astellas Pharma Bull Case</strong></p>
<div class="lb-trans"><p><strong>🐂 Astellas Pharma 看涨案例</strong></p>
</div><h2>Cheap P/E And DCF Gap</h2>
<div class="lb-trans"><h2>便宜的市盈率和 DCF 差距</h2>
</div><ul>
<li>The shares change hands at ¥2,291.50 with a trailing P/E of 14.1x, compared with a peer average P/E of 29.9x and a JP Pharmaceuticals industry average P/E of 15.5x. The price also sits well below a DCF fair value of ¥4,580.24.</li>
<li>Critics highlight that even with this discount, analysts expect earnings to decline by about 11.2% per year over the next three years and revenue to fall roughly 6.2% per year. This means the low P/E and gap to DCF fair value can be read either as an opportunity if you think the modeled earnings slide is too harsh, or as a signal that the market is already factoring in those weaker forward numbers.</li>
</ul>
<div class="lb-trans"><ul>
<li>该股交易价格为 2291.50 日元，市盈率为 14.1 倍，而同行业平均市盈率为 29.9 倍，JP 制药行业平均市盈率为 15.5 倍。该价格也远低于 DCF 公允价值 4580.24 日元。</li>
<li>批评者指出，即使有这种折扣，分析师预计未来三年盈利将下降约 11.2%，收入将下降约 6.2%。这意味着低市盈率和与 DCF 公允价值的差距可以被解读为机会（如果你认为模型化的盈利下滑过于严厉），或者作为市场已经考虑到这些较弱的前瞻性数字的信号。</li>
</ul>
</div><h2>Bear Case Focuses On Shrinking Top Line</h2>
<div class="lb-trans"><h2>看跌案例关注收入萎缩</h2>
</div><ul>
<li>Across the last three semi annual points, revenue progressed from ¥976,702m in the second half of FY 2025 to ¥1,030,114m in the first half of FY 2026 and ¥1,109,131m in the second half. Analyst models referenced in the cautious view nonetheless call for annual revenue declines of around 5.4% in the bearish case and 3.5% in the consensus case over the coming years.</li>
<li>Bears argue that patent expiries on key products and pressure on drug pricing will make it hard to replace revenue. That is reflected in their scenario where revenue is assumed to fall to ¥1,648.6b and earnings to ¥118.0b by about 2028, so the current trailing twelve month net income of ¥291.5b and 13.6% margin are being weighed directly against those projected lower revenue and earnings figures when cautious investors assess how exposed the business might be to loss of exclusivity and policy changes.</li>
</ul>
<div class="lb-trans"><ul>
<li>在过去三个半年度中，收入从 2025 财年下半年的 976,702 百万日元增长到 2026 财年上半年的 1,030,114 百万日元，再到下半年的 1,109,131 百万日元。然而，谨慎观点中提到的分析师模型仍然预测未来几年看跌情况下年收入将下降约 5.4%，共识情况下下降 3.5%。</li>
<li>看跌者认为，关键产品的专利到期和药品定价压力将使得替代收入变得困难。这在他们的情景中反映出来，预计到 2028 年收入将降至 1,648.6 亿日元，盈利降至 1180 亿日元，因此当前的 2915 亿日元净收入和 13.6% 利润率在谨慎投资者评估企业可能面临的独占权丧失和政策变化时，直接与这些预计的较低收入和盈利数字进行权衡。</li>
</ul>
</div><p><strong>🐻 Astellas Pharma Bear Case</strong></p>
<div class="lb-trans"><p><strong>🐻 Astellas Pharma 看跌案例</strong></p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Astellas Pharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p>
<div class="lb-trans"><p>要了解这些结果如何与长期增长、风险和估值相结合，请查看 Simply Wall St 上关于 Astellas Pharma 的完整社区叙事。将该公司添加到您的观察列表或投资组合中，以便在故事发展时收到提醒。</p>
</div><p>With the mix of optimism and concern around Astellas Pharma, it helps to move quickly and look at the details yourself to see what stands out. To weigh both sides of the story, review the 4 key rewards and 1 important warning sign</p>
<div class="lb-trans"><p>在 Astellas Pharma 周围的乐观与担忧的混合中，迅速行动并查看细节以了解哪些内容突出是有帮助的。为了权衡故事的两面，回顾 4 个关键奖励和 1 个重要警示信号。</p>
</div><h2>See What Else Is Out There</h2>
<div class="lb-trans"><h2>查看其他信息</h2>
</div><p>Analysts are modeling annual revenue and earnings declines for Astellas Pharma, which raises questions about how durable the current earnings and margin profile really is for long term holders.</p>
<div class="lb-trans"><p>分析师正在预测 Astellas Pharma 的年收入和盈利下降，这引发了对当前盈利和利润率组合在长期持有者中究竟有多持久的质疑。</p>
</div><p>If shrinking revenue potential worries you, it makes sense to compare this setup with companies screened for resilient performance and lower downside risk using the 46 resilient stocks with low risk scores.</p>
<div class="lb-trans"><p>如果收入潜力缩减让您感到担忧，那么将这种情况与经过筛选的表现稳健且下行风险较低的公司进行比较是有意义的，使用 46 只具有低风险评分的稳健股票。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理您的所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>并且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

Astellas Pharma（TSE:4503）利润率飙升至 13.6% 对看跌的收益叙述构成挑战